Patents by Inventor Stevin Howard Zorn

Stevin Howard Zorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DENDRITIC CELL RECRUITMENT FROM BLOOD TO BRAIN IN NEURODEGENERATIVE DISEASE
    Publication number: 20210181185
    Abstract: The present disclosure provides methods of treating neurodegenerative diseases, including administering agents that block dendritic cells from entering the brain from the blood. The present further describes methods for detecting the selective migration of dendritic cells from blood into brain as a marker of human neurodegenerative disease. The present disclosure further describes methods that can be used to evaluate and compare different embodiments of methods detecting migration of dendritic cells using transgenic mice that overexpress various mutations associated with induction of distinct neurodegenerative disease pathologies.
    Type: Application
    Filed: November 8, 2018
    Publication date: June 17, 2021
    Applicant: MindImmune Therapeutics, Inc.
    Inventors: Brian Michael Campbell, Frank Samuel Menniti, Robert Brelsford Nelson, Stevin Howard Zorn
  • 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine
    Publication number: 20040198734
    Abstract: A compound of the formula 1
    Type: Application
    Filed: April 15, 2004
    Publication date: October 7, 2004
    Applicant: Pfizer Inc
    Inventors: Anton Franz Josef Fliri, Mark Jerome Majchrzak, Patricia Ann Seymour, Stevin Howard Zorn, Hans Rollema
  • Combination treatment for depression, anxiety and psychosis
    Publication number: 20040048869
    Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
    Type: Application
    Filed: September 3, 2003
    Publication date: March 11, 2004
    Applicant: Pfizer Inc
    Inventors: Phillip Branch Chappell, Stevin Howard Zorn
  • Combination treatment for depression, anxiety and psychosis
    Publication number: 20020094986
    Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
    Type: Application
    Filed: December 5, 2001
    Publication date: July 18, 2002
    Applicant: Pfizer Inc
    Inventors: Phillip Branch Chappell, Stevin Howard Zorn